SINGAPORE - Media OutReach Newswire - 22 December 2025 - Pyxis, a leading Singapore-based maritime electrification startup, has secured S$13 million in the first close of its S$18 million growth ...

LONDON, Nov. 18, 2025 /PRNewswire/ -- Compass Box Scotch Whiskymakers announce the launch of Pyxis, a first-of-its-kind AI-powered whisky guide designed to make exploration more personal, effortless, ...

Pyxis Oncology , Inc. (NASDAQ:PYXS) reported the retirement of Pamela Connealy from her roles as Chief Financial Officer and Chief Operating Officer, effective Tuesday. According to a statement based ...

The pre-order price for the Blackmagic PYXIS 12K is now down to $5495, still higher than the $4995 it was launched at as long ago as Friday, but cheaper than the $6595 it was yesterday. We said this ...

At NAB 2025 in Las Vegas, Blackmagic Design announced the PYXIS 12K, a full-frame digital cinema camera with a 12K RGBW sensor, modular build, and cloud-based workflow tools. It’s priced at $4,995 and ...

Having recently trimmed back its pipeline to a sole cancer candidate, Pyxis Oncology has now reduced its head count to match. The Boston biotech is shrinking its workforce by "approximately" 20%, it ...

The completion of the $3.0 million common share repurchase program demonstrates Pyxis Tankers' commitment to returning value to shareholders and potentially enhancing share price. Redemption of all ...

The first reviews of the Blackmagic PYXIS 6K are starting to circulate, with Sean Viljoen’s video of filming with it at the Imire Game Reserve in Zimbabwe showcasing some impressive capabilities. Sean ...

Pyxis Oncology (NASDAQ:PYXS), a biopharmaceutical company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment, has been garnering attention from investors and ...

Shares of Pyxis Oncology (NASDAQ:PYXS) cratered 46% Thursday, the day after the company reported preliminary results from a Phase 1 study for its lead oncology drug candidate, PYX-201, prompting a ...

On Wednesday, Pyxis Oncology, Inc. (NASDAQ:PYXS) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors. Among evaluable Head and ...

Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors. The data presented was in six ...